ƽ

SepMate™-50 (IVD)

Tube for density gradient centrifugation for in vitro diagnostic (IVD) applications

Try SepMate™-50 (IVD) tubes for density gradient centrifugation in your IVD applications. Request a Sample

SepMate™-50 (IVD)

Tube for density gradient centrifugation for in vitro diagnostic (IVD) applications

Catalog #
(Select a product)
Tube for density gradient centrifugation for in vitro diagnostic (IVD) applications
Request Pricing Request Pricing

Product Advantages


  • Eliminates the need for carefully layering blood over the density gradient medium (e.g. ⳾DZ™, etc.)

  • Reduces total centrifuge time to 10 minutes with the brake on for fresh samples

  • Allows fast and easy harvesting of the isolated mononuclear cells by simply pouring off the supernatant

  • Can be combined with Dzٳٱ𳧱™ enrichment cocktails to isolate specific cell types in just 30 minutes

What's Included

  • SepMate™-50 (IVD), 100 Tubes (Catalog #85450)
    • Dispenser box containing 4 bags, 25 Tubes/Bag
  • SepMate™-50 (IVD), 500 Tubes (Catalog #85460)
    • Dispenser box containing 4 bags, 25 Tubes/Bag (Catalog #85450) x 5

What Our Scientist Says

Traditional isolation of PBMCs requires careful layering of blood onto density gradient media prior to centrifugation. We developed SepMate™ to simplify this process, so anyone can isolate PBMCs with a simple pour while maintaining consistency across samples.

Peter MorinTechnical Scientist
Peter Morin, Technical Scientist

Overview

Simplify peripheral blood mononuclear cell (PBMC) isolation by incorporating SepMate™ into your density gradient centrifugation step.

SepMate™ tubes contain an insert that creates a barrier between the density gradient medium and blood, thus eliminating the need for careful blood layering and allowing mononuclear cells to be easily harvested with a simple pour. This product can be used with Dzٳٱ𳧱™ to isolate specific immune cell subsets.

SepMate™-50 is designed for processing 4 to 17 mL of sample.

SepMate™ is manufactured under cGMP and is available as an in vitro diagnostic (IVD) device in Australia, Canada, the European Union (EU), Switzerland, Turkey, the United Kingdom (UK), and the United States. In China, SepMate™ is considered general laboratory equipment by the China Food and Drug Administration (CFDA). The end user is responsible for determining whether the product is suitable for their specific application.

Browse our Frequently Asked Questions (FAQs) on SepMate™.
Contains
Polypropylene tube containing an insert
Subtype
Centrifugation Tubes
Cell Type
B Cells, Dendritic Cells, Monocytes, Mononuclear Cells, NK Cells, T Cells, T Cells, CD4+, T Cells, CD8+, T Cells, Other Subsets, T Cells, Regulatory
Species
Human
Sample Source
Bone Marrow, Whole Blood
Selection Method
Negative
Application
Cell Isolation, In Vitro Diagnostic
Brand
SepMate
Area of Interest
Chimerism, HLA, Immunology

Data Figures

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 1. Recovery of mononuclear cells (MNCs) from peripheral blood using SepMate™-50 versus standard density gradient centrifiguation. Recovery of MNCs from fresh and 48-hour post blood draw enriched by density gradient centrifugation with SepMate™ (purple) or without (grey). There was no significant difference in the recovery of MNCS with and without SepMate™.

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 2. Human CD4+ T Cell Isolation using SepMate™-50 and Dzٳٱ𳧱™ Human CD4+ T Cell Enrichment Cocktail

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
85460, 85450
Lot #
All
Language
MULTI

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (89)

Phenotypically similar but functionally distinct NK cell populations within the human maternal-fetal interface M. Frutoso et al. ImmunoHorizons 2026 Mar

Abstract

AbstractNatural killer (NK) cell function within tissues extends beyond exerting cytotoxicity, encompassing a range of functions that are just starting to become fully elucidated. In the context of human placentation, NK cells play a key role in enabling initial placentation, which is associated with the acquisition of tolerance-like properties. If and to which extent NK cells maintain these tolerance-like properties over the course of human pregnancy is still poorly understood. We asked if NK cells isolated from the decidual-placental interface of full-term human pregnancies are able to exert effector function. We observed a significant and striking lack in the ability of NK cells isolated from the decidual-placental interface (DPI) to produce interferon-g (IFN-γ) in response to the activating cytokines interleukin (IL)-12, IL-15, and IL-18. In contrast, NK cells from the decidua retained their responsiveness to cytokine-mediated activation. Notably, CD103+CD69+ tissue-resident NK cells were present in both DPI and decidua, yet exhibited distinct effector function from one another. Using high-parameter flow cytometry and single-cell sequencing, we found that this functional discrepancy was not directly predictable based on their cell surface phenotype or cell transcript. Together, our findings reveal the presence of distinct functional resident NK cell populations in 2 anatomically adjacent tissues at healthy full-term pregnancies.
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy D. Schmid et al. Nature Communications 2025 Sep

Abstract

Neoadjuvant chemoimmunotherapy offers promise to improve outcomes for patients with resectable non-small cell lung cancer (NSCLC). Yet not all patients derive treatment benefits, and reliable biomarkers of response are still lacking. We here assess the long-term clinical outcome of neoadjuvant chemotherapy and perioperative anti-PD-L1 inhibition in resectable stage IIIA NSCLC in the SAKK 16/14 trial and provide a comprehensive characterization of anti-tumor immune responses for biomarker-based treatment personalization. We report secondary outcomes of median event-free survival (EFS) of 4.0 years and median overall survival not being reached after a median follow-up of 5.4 years. Computer-aided spatial image analysis emphasizes the importance of CD8+ T cell positioning in tumors, and larger tertiary lymphoid structures in pre-treatment biopsies correlate with improved EFS. Genomic techniques reveal the association of intratumoral TCR diversity with response. Finally, circulating proliferating CD39+ PD-1+ CD8+ T cells and elevated levels of CCL15 post-treatment are seen in patients with sustained therapeutic benefit. NCT02572843. Neoadjuvant immunochemotherapy against NSCLC has been tested in clinical trials. Here, the authors follow up longer-term survival and measure immune cell phenotype changes in a single-arm phase II clinical trial of neoadjuvant immunochemotherapy, indicating association of intratumoural TCR diversity and CD8 T cell positioning.
Immunoproteasome remodeling in senescing human macrophages reveals the loss of PA28αβ capping as a hallmark of immunosenescence F. Monittola et al. Communications Biology 2025 Sep

Abstract

Aging negatively impacts proteasome activity and/or content, and this impairment contributes to disrupted protein homeostasis and cellular dysfunction. However, little is known about proteasome complex dynamics during aging, particularly in the context of immunosenescence. Indeed, only limited data are available on the immunoproteasome, a specialized variant expressed in immune cells. We establish an in vitro model of monocyte-derived human macrophages that develop a senescence-like phenotype upon long-term culture. Our data demonstrate that immunoproteasome complexes undergo deep structural and functional alterations, with the downregulation of immunosubunit expression at the mRNA and protein level, uncapping of the 20S catalytic particle by the PA28αβ regulator, and loss of activity. Immunosubunits are partly replaced by their constitutive counterparts with a shift toward the building of 19S-capped 20S complexes to maintain proteostasis. Similar proteasome dynamics are found in the lymph nodes of aged C57BL/6 and BTBR mice, the latter of which have a naturally activated immune system. Overall, these findings propose long-term cultures of human monocyte-derived macrophages as a model to study macrophage senescence. They also provide a molecular rationale for immunoproteasome dysfunction with remodeling of the proteasome, indicating that the loss of the PA28αβ regulator is a critical event and a hallmark of immunosenescence. A study on proteasome complex dynamics in an in vitro model of senescent human macrophages and in the lymph nodes of aged mice reveals immunoproteasome remodeling and the loss of PA28αβ regulator capping as hallmarks of immunosenescence.
Try SepMate™-50 (IVD) tubes for density gradient centrifugation in your IVD applications. Request a Sample